From January 19 to 23 local time, the World Economic Forum Annual Meeting 2026 (the "Winter Davos Forum") was held in Davos, Switzerland. On January 20, He Lifeng, Member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, attended the forum and delivered a speech. On the same day, the Chief Executive Officer of Sino Biopharm (1177.HK) and Chairman of Chia Tai Tianqing, representing Chinese pharmaceutical companies, shared his views at the "Recoding Trade" roundtable forum. He called for breaking down barriers to the cross-border circulation of innovative drugs through mutual trust and recognition, aiming to provide patients worldwide with faster, more affordable, and broader access to treatments. 

He Lifeng stated that in January 2017, President Xi Jinping delivered an important speech at the Davos Forum, which China has diligently implemented, firmly supporting multilateralism and free trade. In recent years, President Xi Jinping has successively proposed four major global initiatives, offering China's solutions to the common problems facing the world. In his speech at the forum, He Lifeng put forward four points: First, we must firmly support free trade and work together to promote inclusive and beneficial economic globalization. Second, we must firmly uphold multilateralism and promote the development of a more just and reasonable international economic and trade order. Third, we must adhere to win-win cooperation, strive to expand the pie of cooperation, and work together to solve development challenges. Fourth, we must adhere to mutual respect and equal consultation, and make good use of dialogue to properly manage differences and resolve problems. He Lifeng also briefed on the Fourth Plenary Session of the 20th CPC Central Committee, emphasizing that China's development will bring important opportunities to the world, and he also engaged in in-depth exchanges with members of the international business community. 

The theme of the Annual Meeting 2026 is "The Spirit of Dialogue". About 3,000 participants from over 130 countries and regions discussed five major topics, including how to strengthen cooperation, unleash new growth drivers, and invest in people. 

Currently, technological innovation is profoundly reshaping the global trade landscape. However, issues such as imbalanced global investment flows, cross-border applications, and large-scale commercialization are prominent. Factors like differing national regulatory frameworks, fragmented standards, geopolitical tension, and a trust deficit have become significant bottlenecks hindering the implementation of innovative technologies, a situation particularly evident in the biopharmaceutical field. 

At the "Recoding Trade" roundtable forum, Mr. Eric Tse pointed out that the key to accelerating the cross-border accessibility of various drugs is to build two major systems: "quality trust" and "evidence trust". Since proposing the establishment of a "Multi-center Clinical Recognition System for the Asia-Pacific and Belt and Road Regions" at 2025 Winter Davos Forum, the initiative has received attention and support from all sectors and has entered a stage of substantive progress. This system, based on unified clinical trial standards (ICH), promotes mutual recognition of multi-center clinical trial results within the region to achieve simultaneous approval and launch of innovative drugs, optimizing the trade system from four dimensions: rules, trust, data, and supply chain. 

The value release of emerging technologies should not be hindered by fragmented rules. The "recoding" of trade is not just a technological upgrade but a systematic reshaping of rules, trust, and collaboration methods. 

In terms of the implementation path, he proposed a progressive approach of "from pilot to expansion". Initially, a core cooperation circle would be formed by influential clinical research institutions in the region. Subsequently, the scope of cooperation would be gradually expanded to deepen collaboration in multiple areas such as real-world studies and post-marketing surveillance. As a representative of a leading industry enterprise, Sino Biopharm will actively participate in the construction of regional pilots. It has reached a consensus with the Shanghai Municipal Government to cooperate in building the Shanghai Biomedical International Alliance, leveraging the power of industrial clusters to support the co-creation of a sustainable and inclusive new trade ecosystem. 

Live Broadcast Preview

On January 22, from 16:15-17:00 Swiss local time, Mr. Eric Tse attended the "Investors and the Patience Premium" roundtable forum to share his views on investment and financing experiences in the biotechnology sector. This session was live-streamed on the official platform of the World Economic Forum. The official website link is as follows: https://www.weforum.org/. 

Declaration: The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 

Source: Xinhua News Agency - World Economic Forum, Embassy of China in Switzerland